Stocks making the biggest moves midday: Broadcom, Chevron, Alibaba, Carnival & more

Chipmaker Broadcom rose ~6% after Apple expanded their multiyear partnership to exceed $30B and drive 15B U.S.-made chips, also expanding a Fort Collins facility. Several stocks swung on company/Street moves: Moderna fell ~7% after Morgan Stanley reiterated equal-weight and lifted its COVID/flu vaccine-driven valuation view (PT to $39 from $33), FuelCell Energy dropped ~12% on a 10.7M-share upsized offering raising $225M gross, and Levi Strauss was down ~2% ahead of results (consensus Q2 revenue $1.52B, +5.1% YoY; EPS 24c). Energy and demand sensitivities also moved: Diamondback jumped >3% as oil prices rose after Trump said the Iran ceasefire is over, while Carnival/airlines fell ~2–4% on higher fuel costs and Bath & Body Works slid >6% after a Goldman downgrade citing potential cannibalization from third-party distribution.

Analysis

AVGO is being rewarded for revenue visibility, but the bigger signal is that Apple is effectively paying up for supply-chain insurance. That tends to pull forward demand for a narrow set of domestic semiconductor capacity, which is constructive for adjacent capex beneficiaries, but it also increases concentration risk: if one customer is large enough to move the stock, the multiple can compress quickly if orders normalize. Over 6-18 months, the real winner is whichever vendor can monetize this as recurring strategic spend rather than one-off design-in revenue.

Energy is the cleanest short-horizon relative-value setup. A crude spike helps OXY/FANG/APA/CVX immediately, but the more durable alpha is in the transport losers: CCL/NCLH/UAL/DAL have limited ability to pass through fuel inflation in real time, so margin pressure shows up before demand destruction does. If oil stays elevated for 1-3 months, the market will likely cut forward earnings for transport faster than it upgrades energy, but if geopolitical risk fades, the transports can rebound harder because the move is being driven more by headline beta than by a structural supply shock.

China internet is trading like a positioning squeeze, not a fundamental inflection. BABA/JD/BIDU can run for days on sector rotation, but without proof of domestic demand stabilization or policy follow-through, the move is vulnerable to a fast fade. FCEL remains the clearest balance-sheet warning: repeated equity issuance in this tape usually signals the business is financing time, not growth, and that can reprice the stock lower again if burn does not improve within the next 1-2 quarters. For MRNA and BBWI, analyst actions are noise unless they translate into better estimates or a cleaner channel structure; otherwise the market is just repricing slower decay, not a new growth path.

Key Decisions for Investors

• Long OXY/FANG vs short CCL/NCLH/UAL for 1-4 weeks; enter on any intraday retracement, target 8-12% relative outperformance, and cover the shorts if Brent drops back through the pre-spike level.
• Buy AVGO only on pullbacks after the gap; avoid chasing the open. If already long, keep the core but hedge with a small short in SOXX/SMH for the next 1-3 months in case the market decides the Apple deal is more customer-concentration than incremental demand.
• Treat BABA/JD/BIDU as a trade, not an investment, until there is evidence of policy or macro follow-through. Fade strength after a 2-day momentum run unless volume and guidance commentary confirm a real earnings revision cycle.
• Avoid FCEL on any bounce; the financing increases dilution risk and should be treated as a liquidity event, not a fundamental re-rate. Reassess only if operating cash burn improves over the next 1-2 quarters.
• No urgency on LEVI or MRNA until the event risk clears; implied volatility suggests the market already expects a large move, so the better setup is to wait for post-print dislocation rather than speculate ahead of the catalyst.